83897-05-6 Usage
Description
21-Acetyloxy DeschloroMoMetasone Furoate is a white solid compound that belongs to the class of corticosteroids. It is a derivative of the corticosteroid MoMetasone, with an acetyloxy group at the 21-position and a furoate group attached to the side chain. This modification enhances its anti-inflammatory and anti-allergic properties, making it a promising candidate for the development of novel topical corticosteroids.
Uses
Used in Pharmaceutical Industry:
21-Acetyloxy DeschloroMoMetasone Furoate is used as an active pharmaceutical ingredient for the preparation of a series of novel topical corticosteroids. These corticosteroids are designed to provide effective treatment for various skin conditions, such as eczema, psoriasis, and dermatitis, by reducing inflammation, itching, and redness.
The unique chemical structure of 21-Acetyloxy DeschloroMoMetasone Furoate allows for targeted delivery to the affected areas, minimizing systemic side effects and improving patient compliance. Its potent anti-inflammatory and anti-allergic properties make it a valuable addition to the existing range of corticosteroid medications, offering new therapeutic options for patients with skin disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 83897-05-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,8,9 and 7 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 83897-05:
(7*8)+(6*3)+(5*8)+(4*9)+(3*7)+(2*0)+(1*5)=176
176 % 10 = 6
So 83897-05-6 is a valid CAS Registry Number.
83897-05-6Relevant articles and documents
Improvements in corticosteroid 21-acetoxy-17α-hydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione synthesis and its use as common intermediate in the synthesis of some impurities related to dexamethasone and mometasone
Das, Saibal Kumar,Dubey, Manoj Kumar,Buchhikonda, Ravinder
, p. 47 - 55 (2019/05/22)
There are quite substantial number of impurities related to dexamethasone or mometasone which cannot be made from respective Active Pharmaceutical Ingredients but from common intermediate 21-acetoxy-17α-hydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione (12). As such, a robust and economical synthesis of this key intermediate is important for delivering a resilient and economically viable supply chain for these impurities. Therefore, it is critical to have a robust and economically viable process to synthesize the intermediate 12 in good yield and quality. We report here an improved synthesis of 12 and eight impurities related to dexamethasone and mometasone from this common intermediate.
